Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
TW |
Intrinsic Value
The intrinsic value of Caliway Biopharmaceuticals Co Ltd (6919) under the Base Case is 0.53 TWD per share. Compared with the current market price of 65.4 TWD, the stock appears Overvalued by 99% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Caliway Biopharmaceuticals Does
Caliway Biopharmaceuticals is a Taiwan-based drug development company that focuses on turning laboratory compounds into prescription medicines. It does not sell a broad catalog of everyday consumer products; instead, it works on a small number of specialty drug candidates, with an emphasis on skin-related and other focused medical uses. Its main customers are not patients directly at first, but healthcare partners such as drug distributors, licensees, and other pharmaceutical companies that help bring approved products to market.
- Headquarters
- Taiwan TW
- IPO date
- Dec 26, 2022
Earnings Waterfall
Caliway Biopharmaceuticals Co Ltd
The intrinsic value for Caliway Biopharmaceuticals Co Ltd (6919) under the Base Case is 0.53 TWD.
Compared with the current market price of 65.4 TWD, the stock appears Overvalued by 99% .